Profusa, Inc. PFSA

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

were originally incorporated under the name "Northview Acquisition Corp." as a blank check company incorporated as a Delaware

corporation and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar

business combination with one or more businesses. As discussed in this Annual Report, we completed the Business Combination on July 11,

is a digital health technology company based in Berkeley, California, that has invested over the last twelve years more than $100 million

Last close 0.84 2026-10-23
Market cap $508.2K 2026-06-30 share count
52-week range 0.70 - 3,000.00

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-107.01

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021
Revenue —$100.0K———
R&D $2.8M$1.6M———
SG&A $24.9M$3.0M———
Total operating expenses $27.7M$4.6M———
Operating income -$27.7M-$4.5M-$1.5M-$1.3M—
Interest expense $2.5M$4.4M———
Pre-tax income —-$8.6M$1.6M$7.7M—
Income tax —$80.5K$456.8K$499.2K—
Net income -$35.8M-$9.2M$1.2M$7.2M—
EPS, basic -107.01-357.140.120.30—
EPS, diluted -107.01-357.140.120.30—
Shares, diluted (wtd. avg.) 334,76225,8445.2M5.2M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021
Cash and equivalents $1.8M$191.0K$142.0K$193.5K$741.2K
Total current assets $3.8M$260.0K$1.6M$511.7K$1.1M
Property, plant and equipment $8.0K————
Total assets $3.8M$3.1M$10.9M$194.7M$193.1M
Accounts payable $7.3M$5.0M———
Short-term debt ——$200.0K——
Total current liabilities $22.3M$57.1M$4.9M$935.8K$106.5K
Total liabilities $30.4M$57.1M$5.1M$1.8M$7.3M
Retained earnings -$160.8M-$125.0M-$3.5M-$620.0K-$5.9M
Total equity -$26.7M-$119.2M-$110.0M-$619.5K-$5.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021
Operating cash flow -$16.2M-$2.1M-$2.1M-$581.2K—
Stock-based compensation $891.0K$21.0K———
Capital expenditure $8.0K————
Investing cash flow -$2.0M$3.0M$185.6M$33.4K—
Financing cash flow $19.8M$2.1M-$183.7M——
Buybacks —$3.2M$184.8M——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-050904.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -40M -20M 0 20M Net income, FY2022: 7.2M Net income, FY2023: 1.2M Revenue, FY2024: 100K Net income, FY2024: -9.2M Net income, FY2025: -35.8M FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2021FY2022FY2023FY2024FY2025
Revenue — — — $100.0K —
Gross profit — — — — —
Net income — $7.2M $1.2M -$9.2M -$35.8M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed Item 1.01
  • Unregistered share sale Item 3.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%